Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies

被引：0
|
作者：
Linda Harris
Tom O’Connell
Jonathan J. Woolley
Gilbert L’Italien
Tamela Martin
Vladimir Coric
James A. Moren
机构：
[1] Biohaven Pharmaceuticals,
[2] Medicus Economics,undefined
[3] American Headache Society,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Breakthrough; Cost; Dihydroergotamine; Intranasal; Medicaid; Migraine, acute; Migraine, prevention; Monoclonal antibody; Monthly migraine day; Triptan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1141 / 1152
页数：11
相关论文
共 50 条
  • [21] Reduction in acute headache medication use with fremanezumab in chronic migraine patients by prior migraine preventive treatment use: Subgroup analysis of the HALO CM study
    Stark, R.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [22] Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients
    Schim, J
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (01) : 49 - 53
  • [23] Persistence, use of resources and costs in patients who start preventive medication for the treatment of migraine in Spain: The persec study
    Irimia, Pablo
    Garcia-Azorin, David
    Nunez, Mercedes
    Cerezo, Silvia Diaz
    De Polavieja, Pepa Garcia
    Panni, Tommaso
    Sicras-Navarro, Aram
    Sicras-Mainar, Antoni
    Ciudad, Antonio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 232 - 232
  • [24] Real-world effectiveness and tolerability of fremanezumab for the preventive treatment of migraine in patients using concomitant gepants for acute treatment in a US neurology practice
    Eugeni, P.
    HEADACHE, 2022, 62 (07): : 927 - 927
  • [25] Individual self-prediction of migraine attacks: longitudinal analysis of cohort of migraine patients using a digital platform
    Prieto, Pablo
    Boucher, Gabriel
    Mian, Alec
    Rosen, Noah
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [26] Individual self-prediction of migraine attacks: longitudinal analysis of cohort of migraine patients using a digital platform
    Prieto, Pablo
    Boucher, Gabriel
    Mian, Alec
    Rosen, Noah
    CEPHALALGIA, 2017, 37 : 275 - 275
  • [27] ONABOTULINUMTOXINA CHANGES CORTICAL EXCITABILITY IN CHRONIC MIGRAINE PATIENTS AFTER PREVENTIVE TREATMENT: OBSERVATIONAL STUDY OVER 12 MONTHS
    Artemenko, Ada
    Shevchenko, Vladlena
    Kurenkov, Alexey
    TOXICON, 2021, 190 : S6 - S6
  • [28] Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older
    Babaei, Mahsa
    Rapoport, Alan M.
    EXPERT REVIEW OF MEDICAL DEVICES, 2023, 20 (06) : 433 - 447
  • [29] SUBCUTANEOUS SUMATRIPTAN IN THE ACUTE TREATMENT OF MIGRAINE IN PATIENTS USING DIHYDROERGOTAMINE AS PROPHYLAXIS
    HENRY, P
    DALLENS, H
    HEADACHE, 1993, 33 (08): : 432 - 435
  • [30] Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans
    Serrano, Daniel
    Buse, Dawn C.
    Kori, Shashi H.
    Papapetropoulos, Sypridon
    Cunanan, Cedric M.
    Manack, Aubrey N.
    Reed, Michael L.
    Lipton, Richard B.
    HEADACHE, 2013, 53 (09): : 1415 - 1429
12345